TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with hematologic malignancies, who are at high risk of complications after conventional myeloablative transplantation~2. Patients must have a 6/6 matched, related donor. Matching at HLA Class II will be based on PCR of sequence specific primers (SSP). Among family member transplants, serologic matching at Class I is sufficient~3. Patient age greater than 18~4. Performance status 0-2~5. Life expectancy of \> 100 days without transplantation~6. Written informed consent must be obtained in all cases from the patient~Exclusion Criteria:~1. Pregnancy~2. Prior Allogeneic Stem Cell Transplantation from any donor~3. Evidence of HIV infection or active Hepatitis B or C infection~4. Heart failure uncontrolled by medications~5. Total bilirubin \> 2.0 mg/dl that is due to hepatocellular dysfunction~6. AST \> 90~7. Cholesterol \> 300 mg/dl or Triglycerides \> 400 mg/dl while adequately treated~8. Uncontrolled bacterial, viral or fungal infection~9. Requirement for voriconazole at the time of hospital admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Siro/MMF (Type: EXPERIMENTAL): Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF)
- Siro/MMF/Bort (Type: EXPERIMENTAL): Sirolimus, Mycophenolate Mofetil, and Bortezomib as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF) Bortezomib (Velcade) \*added with study reopening in 2012

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* Patients with acute leukemia, lymphoma that failed to respond or relapsed after chemotherapy or CML beyond first chronic phase.~* Patients with aplastic anemia or myelodysplasia which failed to respond to primary therapy are eligible.~* Patients with low grade lymphoma or CLL will only be eligible if they failed two chemotherapy regimens and have stage IV disease.~* Patients must be \<age 50 with a related haploidentical donor (phenotypically one, two or three HLA A, B and DR antigen mismatched) donor.~* Patients should have adequate hepatic and renal function with a bilirubin of less than or equal to 1.5mg%, SGPT less than or equal to 3x the upper limits of normal, and creatine less than or equal to 1.5mg%.~* Patients with serious intercurrent medical illness are not eligible.~* Patients and their donors must provide written informed consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Megadose T cell depleted (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of the French Version of the Back Belief Questionnaire

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient has had back pain for at least 3 months~Exclusion Criteria:~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant~* The patient is breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic back pain patients (Type: None): Patients who have had back pain for at least three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 50 years old~* Asian ethnicity~* Group 1: Cognitively intact healthy volunteers defined by Cumulative Illness Rating Scale for Geriatrics rating of ≤ 2 for all categories except for the category psychiatric illness which should have a rating of 0 and a CDR of 0 within 1 year prior to the visit.~OR~Group 2a: AD patients clinically diagnosed with mild AD (according to the National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria (McKhann et al., 1984)) with Clinical Dementia Rating-1~OR~Group 2b: AD patients clinically diagnosed with moderate AD (according to the National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria (McKhann et al., 1984)) with Clinical Dementia Rating-2~- Written informed consent provided according to local regulations.~Exclusion Criteria:~* Group 1 only: Current diagnosis of AD or other dementias according to National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria (McKhann et al.,1984 )~* Group 2 only: Change in dose within 2 months prior to visit of AD medication (e.g. donepezil, rivastigmine, galantamine or memantine)~Group 1 and 2:~* Diagnosis of significant neurological disease (for Groups 2a and 2b: other than AD), including vascular dementia according to National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria, cerebral tumour, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, seizures, major depression, schizophrenia and other entities~* Use of vitamins supplements (only vitamins supplements C and D are allowed) for 3 months prior to the visit~* Use of vitamin B injections~* Alcohol or drug abuse as per investigator's judgement~* Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements~* Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mild and Moderate Alzheimer's Disease (Type: None): None
- Cognitively intact healthy people (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for SWL at St. Joseph's Hospital;~* 18 years of age or older;~* Willing and able to complete Questionnaires;~* Willing to submit urine sample for analysis at Day 7;~* Able to read and speak English.~Exclusion Criteria:~* Pre-SWL urine analysis positive for nitrites or urine culture reveals \>105 CFU/ml of bacteria (positive urine culture);~* Taking antibiotics for UTI or other cause;~* Requires an antibiotic post SWL;~* Suspected struvite stone (based on previous stone analysis, or partial staghorn);~* Presence of nephrostomy tube;~* Requiring cystoscopy on the day of SWL;~* Requiring ureteral stent on the day of SWL;~* Presence of indwelling urinary catheter or on regular clean intermittent catheterization (CIC);~* Presence of urinary diversion (ie: ileal conduit);~* Any history of urosepsis;~* Known allergic reaction to ciprofloxacin/quinolones;~* Patient known to be pregnant;~* Previous randomization in this trial;~* In the opinion of the urologist, it is not in the patient's best interest to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Ciprofloxacin (Type: ACTIVE_COMPARATOR): Ciprofloxacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: [S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 1 or 2 diabetes mellitus, with painful, distal, symmetrical, sensorimotor polyneuropathy~* Patients at screening must have a score \>/=40 mm on the pain visual analogue scale~Exclusion Criteria:~* Patients with significant hepatic impairment~* Patients with other severe pain, that may impair the self-assessment of the pain due to DPN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Treatment (Type: EXPERIMENTAL): \[S,S\]-reboxetine
- Standard Care (Type: OTHER): Standard Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ventilated ELBW (401-1000 grams) infants~* 23 to 30 weeks' gestation~* umbilical arterial catheter placed during newborn resuscitation~Exclusion Criteria:~* presence of complex congenital anomalies or chromosomal abnormality~* presence of central nervous system malformation~* infants with hydrops fetalis~* infants in extremis~* infants with early (\<3 hour of age) intraventricular hemorrhage

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- Hypercapnia (Type: PLACEBO_COMPARATOR): Hypercapnic ventilation. The goal will be to maintain transcutaneous CO2 55 mm Hg (50-60 mm Hg) during the first week of life, or until extubation. A written, laminated hypercapnic ventilator algorithm will be placed at the bedside.
- Normocapnia (Type: ACTIVE_COMPARATOR): Normocapnic ventilation. The goal will be to maintain transcutaenous CO2 40 mm Hg (35-45 mm Hg) during the first week of life, or until extubation. A written, laminated normocapnic ventilator algorithm will be placed at the bedside.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be \< 45 years of age and ≥ 28 days old~* Patients with high risk, advanced or poorly responding haematological disease for which there is published evidence that haematopoietic stem cell transplantation using myeloablative conditioning is likely to be effective~* The individual patient's disease status is such that there is no alternative therapy likely to achieve cure or provide a significant prolongation of disease-free survival~* Left ventricular ejection fraction \>45%~* Transaminases and bilirubin \< twice the upper limit of the normal range~* Creatinine clearance \> 60mls/min~* Comorbidity index of 0 or 1~Exclusion Criteria:~* Patients with a suitably matched sibling donor or 10/10 unrelated volunteer donor available within an acceptable time period.~* Pregnancy or breastfeeding.~* Evidence of HIV or HTLV (I+II) infection or known HIV or HTLV positive serology~* Current active serious infection, in particular uncontrolled fungal infection -Previous irradiation that precludes the safe administration of an additional dose of 13- 14.4 Gy of total body irradiation (TBI) in patients aged 2-45 years~* Prior autograft~* CML in first chronic phase responding to Imatinib or refractory blast crisis~* Patients with acute leukaemia in morphological relapse/ persistent disease (defined as \> 5% blasts in normocellular bone marrow)~* Patients with acute myeloid leukaemia with relapse/persistent disease unresponsive to re-induction chemotherapy (defined as \>20% blasts in normocellular bone marrow)~* Malignant disease that is refractory to or progressive on salvage therapy~* Myelofibrosis.~* Aplastic anaemia

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine + Cyclophosphamide + TBI (Type: EXPERIMENTAL): Patients aged 2-45 years (excluding AML, JMML and MDS patients aged \<16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Fludarabine 25mg/m\^2/day day -8 to -6 (total 75mg/m\^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions
- Busulfan + Cyclophosphamide + Melphalan (Type: EXPERIMENTAL): Patients aged \< 2 years and AML, JMML and MDS patients \<16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m\^2 day -2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EMMA-1 (Erbitux for Multiple Myeloma)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple myeloma diagnosed according to the Durie-criteria in stage II or III (Salmon and Durie)~* Measurable disease~* Refractory or relapsed disease after at least one line of treatment~* Male or female \>= 18 years of age~* Life expectancy \> 12 weeks~* ECOG performances status 0-2~* If of childbearing potential, willingness to use effective contraceptive method for the study duration and 6 months post-dosing.~* No surgery, radiotherapy or chemotherapy or any investigational agent within 30 days of study entry~* Signed written informed consent~Exclusion Criteria:~* Asecretory multiple myeloma~* Patients eligible and willing to undergo high dose chemotherapy followed by autologous stem cell transplantation~* Prior allogeneic transplantation~* Prior antibody or EGFR-pathway targeting therapy~* Severe cardiovascular disease like functionally restricting heart rhythm disturbance or heart malformation or severe hypertension, or cardiac insufficiency \> NYHA-II~* HIV Infection, Hepatitis B or C~* Brain disorders, psychiatric illness~* Insufficient bone marrow reserve (Leucocytes \< 1500/µl; Thrombocytes \< 50000/µl)~* Creatinine-Clearance \< 30 ml/min or Crea \> 3.0 mg/dl~* Bilirubin \> 2 mg/dl; ASAT, ALAT \> 100 U/l~* Pregnancy (absence confirmed by serum/urine beta-HCG) or breast-feeding~* FEV1 \< 50% of the reference value~* Active secondary malignancy~* Legal incapacity or limited legal capacity~* Having participated in another clinical trial or any investigational agent in the preceding 30 days~* Known allergic/hypersensitivity reaction to any compounds of the treatment~* Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent~* Known drug abuse/alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab + Dexamethasone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Campath Maintenance in Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment in this study is open to patients 18 years of age with confirmed chronic lymphocytic leukemia, a clinical response of stable disease or better to previous treatment, and an Eastern Cooperative Oncology Group performance status of 0-2~Exclusion Criteria:~* Treatment failure in more than 3 prior regimens~* Active secondary malignancy~* Central nervous system involvement with CLL~* History of significant allergic reaction to antibody therapies that required discontinuation of the antibody therapy~* History of HIV positivity~* Hepatitis C virus (HCV) positivity based upon core antigen testing~* Active infection, requiring treatment with antibiotic, antiviral, or antifungal agents~* Pregnancy or lactation~* Other severe, concurrent diseases or mental disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Campath maintenance treatment (Type: OTHER): Single arm, open label trial of Campath on a maintenance schedule for patients who have had a response to prior conventional chemotherapy. Treatments consist of dose escalation (3, 10 and 30mg) during week 1 followed by weekly dosing of Campath at 30 mg once weekly for 7 weeks followed by Campath 30 mg every 2 weeks for 16 weeks followed by Campath 30 mg once every 3 weeks for 24 weeks. Total duration of treatment up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18~* histologically confirmted advanced colorectal cancer~* ECOG PS 0-2~* expected life span more than 3months~* normal bone marrow, liver, renal function~Exclusion Criteria:~* 5-FU, oxaliplatin, irinotecan or Metformin Allergic history~* Lactic acidosis, metabolic acidosis~* active infection or severe neuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOLFOX6+Metformin/FOFIRI+Metformin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: N-acetylcysteine Effects on Tetrahydrocannabinol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Exposed to Cannabis at least once in lifetime~Exclusion Criteria:~* Cannabis Naive~* Individuals with a documented allergy to N-acetylcysteine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Active N-acetylcysteine and Active Delta-9-THC (Type: EXPERIMENTAL): None
- Placebo and Active Delta-9-THC (Type: PLACEBO_COMPARATOR): None
- Active N-acetylcysteine and Placebo (Type: EXPERIMENTAL): None
- Placebo and Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility